Prestige Consumer Healthcare (PBH) to Release Quarterly Earnings on Thursday

Prestige Consumer Healthcare (NYSE:PBH) is anticipated to announce its earnings results before the market opens on Thursday, February 13th. Analysts expect the company to announce earnings of $1.18 per share and revenue of $287.07 million for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The company had revenue of $283.79 million during the quarter, compared to analysts’ expectations of $282.09 million. During the same period in the prior year, the company posted $1.07 EPS. The firm’s revenue for the quarter was down .9% on a year-over-year basis. On average, analysts expect Prestige Consumer Healthcare to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Prestige Consumer Healthcare Trading Up 0.1 %

NYSE:PBH opened at $75.90 on Thursday. The stock has a market cap of $3.75 billion, a price-to-earnings ratio of 18.47, a price-to-earnings-growth ratio of 2.15 and a beta of 0.50. Prestige Consumer Healthcare has a one year low of $60.00 and a one year high of $86.36. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56. The business’s 50-day simple moving average is $79.29 and its 200 day simple moving average is $75.25.

Insiders Place Their Bets

In related news, CEO Ronald M. Lombardi sold 10,875 shares of the company’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the completion of the transaction, the chief executive officer now directly owns 320,952 shares in the company, valued at $26,510,635.20. This represents a 3.28 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Mary Beth Fritz sold 9,885 shares of the firm’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $81.97, for a total value of $810,273.45. Following the completion of the sale, the senior vice president now owns 18,835 shares in the company, valued at $1,543,904.95. The trade was a 34.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 38,810 shares of company stock valued at $3,187,300 over the last 90 days. 1.60% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Sidoti lowered Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price on the stock. in a research report on Monday, December 9th. StockNews.com upgraded shares of Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Friday, January 24th. DA Davidson reissued a “buy” rating and issued a $95.00 target price on shares of Prestige Consumer Healthcare in a research report on Monday, November 11th. Finally, Raymond James raised shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $85.25.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.